Calling a compound a GH secretagogue does not establish its net effect on body fat. A pathway description is only part of the question. The outcome that matters is what happens to a defined measure of adiposity in a particular population under controlled conditions.
A mouse study of GH-independent adiposity effects reported increased adiposity with ipamorelin in the models studied. This is not proof that people using ipamorelin will gain fat. It is evidence against assuming that all of its effects can be reduced to a simple GH-to-fat-loss story.
Follow the endpoint, not the nickname
Body weight, abdominal circumference, fat mass and lean mass are different measurements. A scale change cannot show which compartment changed, and an improved photograph does not isolate a pharmacological effect from training or food intake. Claims should name the actual measurement rather than switching between these outcomes.
Appetite is another separate question. Feeling hungrier, eating more and accumulating more fat are not identical observations. A study must measure the relevant link instead of relying on a presumed chain of effects. Likewise, absence of a noticeable appetite change would not prove a particular body-composition result.
The animal finding is useful precisely because it encourages a more complete hypothesis. An investigator should consider effects outside the headline pathway and test the net outcome. The wrong response would be to replace “guaranteed fat loss” with “guaranteed fat gain”; both overreach the available model.
For a reader evaluating a proposed human benefit, the missing evidence is a controlled, sufficiently long study of the exact intervention with credible body-composition measurements and adverse-event reporting. Comparisons also need to account for concurrent weight-loss medicines and lifestyle changes.
The responsible conclusion is uncertainty about human fat-loss efficacy, not a hidden fat-loss protocol. Animal results help define what needs testing. They do not establish an indication, authenticate a catalog product, or determine whether an individual should pursue endocrine treatment.